Deep learning for early osteoporosis risk prediction

Scynex­is is pulling its vagi­nal in­fec­tion drug Brex­afemme (ibrex­a­fungerp) from the mar­ket and plac­ing a tem­po­rary hold on on­go­ing clin­i­cal tri­als due to con­t­a­m­i­na­tion risk

Af­ter throw­ing ac­cu­sa­tions of re­tal­i­a­tion and steal­ing trade se­crets in court, Il­lu­mi­na and di­ag­nos­tics com­pa­ny Guardant Health have come to a three-year agree­ment that in­cludes